{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T02:40:58Z","timestamp":1785552058687,"version":"3.56.0"},"reference-count":15,"publisher":"SMC Media","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Secukinumab is an inhibitor of interleukin IL-17A, and is mainly used in the treatment of psoriasis, psoriatic arthritis and ankylosing spondylitis. Although rarely, this drug may induce paradoxical reactions, such as cutaneous vasculitis. Worldwide, only four previous cases of vasculitis induced by secukinumab have been reported. We herein report the first case described in Brazil of cutaneous vasculitis due to secukinumab in a patient with peripheral spondyloarthritis who demonstrated good resolution after withdrawal of the drug and initiation of etanercept. Clinicians should be aware of this rare but potentially serious adverse effect of secukinumab.<\/jats:p>","DOI":"10.12890\/2020_001815","type":"journal-article","created":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T09:52:37Z","timestamp":1621936357000},"source":"Crossref","is-referenced-by-count":7,"title":["Cutaneous Vasculitis During Secukinumab Treatment"],"prefix":"10.12890","volume":"7","author":[{"given":"Camila da Silva Cendon","family":"Duran","sequence":"first","affiliation":[{"name":"Hospital das Cl\u00ednicas da Universidade de S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mittermayer Barreto","family":"Santiago","sequence":"first","affiliation":[{"name":"Hospital Universit\u00e1rio Professor Edgard Santos, Universidade Federal da Bahia, Salvador, Bahia, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10397","published-online":{"date-parts":[[2020,7,28]]},"reference":[{"key":"10.12890\/2020_001815_ref1","doi-asserted-by":"crossref","unstructured":"<li>Carron P, De Craemer AS, Van den Bosch F. Peripheral spondyloarthritis: a neglected entity\u2013state of the art. <em>RMD Open<\/em> 2020;<strong>6<\/strong>:e001136.<\/li>","DOI":"10.1136\/rmdopen-2019-001136"},{"key":"10.12890\/2020_001815_ref2","doi-asserted-by":"crossref","unstructured":"<li>Kiltz U, Sfikakis PP, Gaffney K, Sator PG, von Kiedrowski R, Bounas A, et al. Secukinumab use in patients with moderate to severe psoriasis, psoriatic arthritis and ankylosing spondylitis in real-world setting in Europe: baseline data from SERENA study. <em>Adv Ther<\/em> 2020;<strong>37<\/strong>(6):2865\u20132883.<\/li>","DOI":"10.1007\/s12325-020-01352-8"},{"key":"10.12890\/2020_001815_ref3","doi-asserted-by":"crossref","unstructured":"<li>van Mens LJJ, van de Sande MGH, Menegatti S, Chen S, Blijdorp ICJ, de Jong HM, et al. Brief report: interleukin-17 blockade with secukinumab in peripheral spondyloarthritis impacts synovial immunopathology without compromising systemic immune responses. <em>Arthritis Rheumatol<\/em> 2018;<strong>70<\/strong>:1994\u20132002.<\/li>","DOI":"10.1002\/art.40581"},{"key":"10.12890\/2020_001815_ref4","doi-asserted-by":"crossref","unstructured":"<li>Toussirot \u00c9, Aubin F. Paradoxical reactions under TNF-? blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview. <em>RMD Open<\/em> 2016;<strong>2<\/strong>:e000239.<\/li>","DOI":"10.1136\/rmdopen-2015-000239"},{"key":"10.12890\/2020_001815_ref5","doi-asserted-by":"crossref","unstructured":"<li>Puig L. Paradoxical reactions: anti-tumor necrosis factor alpha agents, ustekinumab, secukinumab, ixekizumab, and others. <em>Curr Probl Dermatol<\/em> 2018;<strong>53<\/strong>:49\u201363.<\/li>","DOI":"10.1159\/000479475"},{"key":"10.12890\/2020_001815_ref6","doi-asserted-by":"crossref","unstructured":"<li>Navarro-Trivi\u00f1o FJ, Sanchez-Parera R, Ruiz-Villaverde R. Secukinumab-induced paradoxical hidradenitis suppurativa. <em>Dermatol Ther<\/em> 2020;<strong>33<\/strong>:e13150.<\/li>","DOI":"10.1111\/dth.13150"},{"key":"10.12890\/2020_001815_ref7","doi-asserted-by":"crossref","unstructured":"<li>Munera-Campos M, Ballesca F, Carrascosa JM. Paradoxical reactions to biologic therapy in psoriasis: a review of the literature. <em>Actas Dermosifiliogr<\/em> 2018;<strong>109<\/strong>:791\u2013800.<\/li>","DOI":"10.1016\/j.adengl.2018.09.012"},{"key":"10.12890\/2020_001815_ref8","doi-asserted-by":"crossref","unstructured":"<li>Chelli C, Loget J, Vanhaecke C, Durlach A, Gagneux-Lemoussu L, Soriano C, et al. Cutaneous vasculitis with gut involvement during secukinumab treatment for psoriatic arthritis. <em>Acta Derm Venereol<\/em> 2020;<strong>100<\/strong>:adv00077.<\/li>","DOI":"10.2340\/00015555-3435"},{"key":"10.12890\/2020_001815_ref9","doi-asserted-by":"crossref","unstructured":"<li>Dogra S, Bishnoi A, Narang T, Handa S. Secukinumab-induced paradoxical pustular psoriasis. <em>Clin Exp Dermatol<\/em> 2019;<strong>44<\/strong>:72\u201373.<\/li>","DOI":"10.1111\/ced.13731"},{"key":"10.12890\/2020_001815_ref10","doi-asserted-by":"crossref","unstructured":"<li>Barrado-Sol\u00eds N, Rodrigo-Nicol\u00e1s B, De la Morena-Barrio I, P\u00e9rez-Pastor G, Sanchis-S\u00e1nchez C, Tom\u00e1s-Cabedo G, et al. Report of two cases of Beh\u00e7et's disease developed during treatment with secukinumab. <em>J Eur Acad Dermatol Venereol<\/em> 2020 Apr 10. doi: 10.1111\/jdv.16454 [Epub ahead of print].<\/li>","DOI":"10.1111\/jdv.16454"},{"key":"10.12890\/2020_001815_ref11","doi-asserted-by":"crossref","unstructured":"<li>Wollina U, Sch\u00f6nlebe J, F\u00fcrll C. Pyoderma gangrenosum induced by secukinumab - a late paradoxical drug reaction. <em>Dermatol Ther<\/em> 2020;<strong>33<\/strong>:e13161.<\/li>","DOI":"10.1111\/dth.13161"},{"key":"10.12890\/2020_001815_ref12","doi-asserted-by":"crossref","unstructured":"<li>Costa-Moreira P, Lopes S, Santos AL, Pedrosa AF, Andrade P, Portugal R, et al. Leukocytoclastic vasculitis related to ustekinumab in a Crohn's disease patient: first case report and literature review. <em>J Crohns Colitis<\/em> 2020;<strong>14<\/strong>:274\u2013276.<\/li>","DOI":"10.1093\/ecco-jcc\/jjz128"},{"key":"10.12890\/2020_001815_ref13","doi-asserted-by":"crossref","unstructured":"<li>Ramos-Casals M, Brito-Zer\u00f3n P, Mu\u00f1oz S, Soria N, Galiana D, Bertolaccini L, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. <em>Medicine (Baltimore)<\/em> 2007;<strong>86<\/strong>:242\u2013251.<\/li>","DOI":"10.1097\/MD.0b013e3181441a68"},{"key":"10.12890\/2020_001815_ref14","doi-asserted-by":"crossref","unstructured":"<li>Saint Marcoux B, De Bandt M. Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France. <em>Joint Bone Spine<\/em> 2006;<strong>73<\/strong>:710\u2013713.<\/li>","DOI":"10.1016\/j.jbspin.2006.02.010"},{"key":"10.12890\/2020_001815_ref15","doi-asserted-by":"crossref","unstructured":"<li>Villani A, De Fata Salvatores G, Nappa P, Megna M, Fabbrocini G, Napolitano M. Cutaneous leucocytoclastic vasculitis during secukinumab treatment. <em>G Ital Dermatol <\/em>Venereol 2019 Jan 9. doi: 10.23736\/S0392-0488.18.06203-X [Epub ahead of print]. <\/li>","DOI":"10.23736\/S0392-0488.18.06203-X"}],"container-title":["European Journal of Case Reports in Internal Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.ejcrim.com\/index.php\/EJCRIM\/article\/download\/1815\/2267","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ejcrim.com\/index.php\/EJCRIM\/article\/download\/1815\/2268","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ejcrim.com\/index.php\/EJCRIM\/article\/download\/1815\/2268","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T13:35:32Z","timestamp":1756474532000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ejcrim.com\/index.php\/EJCRIM\/article\/view\/1815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,28]]},"references-count":15,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.12890\/2020_001815","relation":{"has-manifestation":[{"id-type":"other","id":"1-63-1815-g2267","asserted-by":"subject"},{"id-type":"other","id":"1-63-1815-g2268","asserted-by":"subject"}],"is-part-of":[{"id-type":"other","id":"1-63","asserted-by":"subject"}]},"ISSN":["2284-2594"],"issn-type":[{"value":"2284-2594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,28]]}}}